SCHEMBL3266795

SCHEMBL3266795

COc1ccccc1CNc1ccc2cc(NCc3ccccc3OC(F)(F)F)ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 7/20 0.47
CYP2C19 P33261 7/20 0.47
CYP1A2 P05177 6/20 0.47
CYP3A4 P08684 6/20 0.47
TSHR P16473 5/20 0.47
HSD17B10 Q99714 5/20 0.47
ALOX15 P16050 4/20 0.47
MAPK1 P28482 5/20 0.46
CYP2C9 P11712 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 6/20 0.44
ALDH1A1 P00352 3/20 0.44
NPC1 O15118 2/20 0.44
MAPT P10636 2/20 0.44
RAB9A P51151 2/20 0.44
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267065 0.91 MEN1 (0.53) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3268616 0.86 PDGFRB (0.53) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3271133 0.85 KCNN3 (0.39) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3267015 0.85 MEN1 (0.47) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3267055 0.81 LMNA (0.53) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3266948 0.81 MAPT (0.46) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3268014 0.81 MAPT (0.43) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3273187 0.81 MEN1 (0.43) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3267291 0.81 MEN1 (0.43) CYP2D6CYP2C19CYP1A2CYP3A4TSHR
SCHEMBL3268321 0.81 CYP1A2 (0.53) CYP2D6CYP2C19CYP1A2CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US claimed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US claimed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP claimed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US claimed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO claimed
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US disclosed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP disclosed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088451-A1 QUINOLINES HTR5A, HTR1A, HTR1E CYP2D6 250/4885CYP2C19 288/4885CYP1A2 161/4885
US-20120136018-A1 QUINOLINES HTR5A, HTR1A, HTR1E CYP2D6 250/4885CYP2C19 288/4885CYP1A2 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.